122 related articles for article (PubMed ID: 12207795)
1. Immunohistochemical study of a case of uterine leiomyoma showing massive lymphoid infiltration and localized vasculitis after LH-RH derivant treatment.
Ohmori T; Wakamoto R; Lu LM; Okada K; Nose M
Histopathology; 2002 Sep; 41(3):276-7. PubMed ID: 12207795
[No Abstract] [Full Text] [Related]
2. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis.
McClean G; McCluggage WG
Int J Surg Pathol; 2003 Oct; 11(4):339-44. PubMed ID: 14615835
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry of vascular changes in leuprolide acetate-treated leiomyomas.
Mesia AF; Gahr D; Wild M; Mittal K; Demopoulos RI
Am J Obstet Gynecol; 1997 May; 176(5):1026-9. PubMed ID: 9166163
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyoma with massive lymphoid infiltration: case report and review of the literature.
Paik SS; Oh YH; Jang KS; Han HX; Cho SH
Pathol Int; 2004 May; 54(5):343-8. PubMed ID: 15086839
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
6. Massive lymphocytic infiltration of uterine leiomyomas associated with GnRH agonist treatment.
Bardsley V; Cooper P; Peat DS
Histopathology; 1998 Jul; 33(1):80-2. PubMed ID: 9726054
[TBL] [Abstract][Full Text] [Related]
7. [Massive pseudo-lymphomatous lymphoid infiltrate and vasculitis in uterine leiomyoma treated with LH-RH analogues].
Salinas-Martín MV; Carranza-Carranza A; Mendoza-García E
Med Clin (Barc); 2007 Jul; 129(6):238. PubMed ID: 17678609
[No Abstract] [Full Text] [Related]
8. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
9. [A role of growth factors in development of various histological types of uterine leiomyoma].
Kogan EA; Ignatova VE; Rukhadze TN; Kudrina EA; Ishchenko AI
Arkh Patol; 2005; 67(3):34-8. PubMed ID: 16075611
[TBL] [Abstract][Full Text] [Related]
10. Massive ascites after leuprolide acetate administration for the treatment of leiomyomata uteri.
Lee MJ; Kazer RR
Fertil Steril; 1992 Aug; 58(2):416-8. PubMed ID: 1633912
[TBL] [Abstract][Full Text] [Related]
11. Expression of proliferating cell nuclear antigen and bcl-2 during a pseudomenopausal state induced by presurgical treatment of uterine leiomyomas with gonadotropin-releasing hormone analogues plus tibolone.
De Falco M; Staibano S; Pollio F; Salvatore G; Pontillo M; Ciociola F; Mansueto G; Di Lieto A
Int J Gynecol Pathol; 2005 Jul; 24(3):286-91. PubMed ID: 15968206
[No Abstract] [Full Text] [Related]
12. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
13. Effects of leuprolide acetate on treatment of leiomyomata--clues to mechanisms of action.
Demopoulos RI; Mesia AF
Adv Anat Pathol; 1998 Mar; 5(2):129-36. PubMed ID: 9868519
[No Abstract] [Full Text] [Related]
14. Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Huang SC; Tang MJ; Cheng YM; Hsu KF; Ho CL; Chou CY
J Clin Endocrinol Metab; 2003 Oct; 88(10):5009-16. PubMed ID: 14557488
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
Malik M; Britten J; Cox J; Patel A; Catherino WH
Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
[TBL] [Abstract][Full Text] [Related]
16. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas.
Rein MS; Barbieri RL; Welch W; Gleason RE; Caulfield JP; Friedman AJ
Obstet Gynecol; 1993 Dec; 82(6):901-5. PubMed ID: 8233262
[TBL] [Abstract][Full Text] [Related]
17. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
18. [Use of LH-RH agonists in uterine leiomyoma].
Maheux R
J Gynecol Obstet Biol Reprod (Paris); 1990; 19(5):603-6. PubMed ID: 2212519
[No Abstract] [Full Text] [Related]
19. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS
Fertil Steril; 1992 Aug; 58(2):413-5. PubMed ID: 1633911
[TBL] [Abstract][Full Text] [Related]
20. [Size reduction of uterine myomas with monthly administered leuprolide acetate].
Cheviakoff S; Bocaz JA; Martínez L; Romero C
Rev Chil Obstet Ginecol; 1994; 59(6):416-20; discussion 420-1. PubMed ID: 7569160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
